Although expected, the regulatory approval to commence a Phase IIb trial of RPL554 as maintenance therapy in COPD demonstrates both the broad potential utility of RPL554 and Verona’s intention to maximise the compound’s clinical and commercial potential through development across multiple, large respiratory indications and settings. We continue to believe that RPL554 could represent a rare novel addition to the treatment arsenal in COPD and potentially Cystic Fibrosis (Phase IIa data expected Q ....
